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Abstract Cannabis consumption is temporally associated
with the development of first episode psychosis (FEP).
Whether or not the chronic use of this substance induces
structural brain changes that may be responsible for the
cognitive and psychological disturbances in this disorder is
still matter of debate. To address this issue, we compared
the magnetic resonance imaging (MRI)-assessed grey
(GM) and white matter (WM) changes in young FEP
patients between users versus non-users of cannabis. This
prospective study included 50 consecutive FEP subjects: 33
users (22.7 ± 4.1 years, 4 women) and 17 non-users
(23.9 ± 4.2 years, 10 women). Users were further divided
into 15 heavy (23.3 ± 4.5 years, 2 women) and 18 light
users (22.2 ± 3.8 years, 2 women) according to their
lifetime cannabis use. Voxel-based-morphometry (VBM)
analysis of GM and tract-based-spatial-statistics (TBSS)
analysis of WM were performed. Age and gender were
used as non-explanatory co-regressors. There were no
supra-threshold differences between user and non-user
groups for both GM and WM parameters. This was also the
case when only heavy users were compared to non-users.
Multivariate models controlling for age and gender con-
firmed these findings. We found no evidence for cannabis
consumption related alterations in GM or WM in FEP
subjects. Due to the strict correction for multiple compar-
isons and sample size, we cannot formally exclude subtle
morphometric changes associated with cannabis con-
sumption. However, even if present, such potential altera-
tions would be of low magnitude.
Keywords Psychosis  Cannabis  VBM  TBSS
Abbreviations
BPRS Brief psychiatric rating scale
DTI Diffusion tensor imaging
FA Fractional anisotropy
FEP First episode psychosis
GAF Global assessment of functioning
GM Grey matter
LD Longitudinal diffusivity
MD Mean diffusivity
RD Radial diffusivity
TAP Test of attentional performance
TBSS Tract-based-spatial-statistics
TFCE Threshold-free cluster enhancement
VBM Voxel-based-morphometry
WM White matter
WMS-R Wechsler memory scale: revised
Introduction
First episode psychosis (FEP) is a major health problem in
young adults with a reported incidence rate of at least 1.5 %
per year in urban areas (Amminger et al. 2006). Cannabis use
is very frequent in all stages of psychosis (Regier et al. 1990)
and represents one of its main risk factors (Semple et al.
2005; Henquet et al. 2005; Moore et al. 2007). Previous
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studies have demonstrated alterations in both grey matter
(GM) [review see e.g. (Honea et al. 2005; Glahn et al. 2008;
Fornito et al. 2009; Fusar-Poli et al. 2011)] and white matter
(WM) [review see e.g. (Kyriakopoulos and Frangou 2009)]
in at-risk individuals and patients with early stages of psy-
chosis. Given the frequency of moderate to heavy cannabis
use in these groups, it has been thought that the chronic use of
this substance partly contributes to these structural changes
by affecting both GM densities and WM microstructure.
Most previous studies focused on FEP or early psychosis in
line with the hypothesis of an early toxic effect of cannabis
on brain maturation. Cross-sectional comparisons revealed
decreased GM densities in cannabinoid receptor rich areas
(i.e. temporal fusiform gyrus, parahippocampal gyrus,
insular cortex, precuneus, paracingulate gyrus, dorsolateral
prefrontal cortex, cerebellum) of these patients (Szeszko
et al. 2007; Bangalore et al. 2008; Cohen et al. 2011; James
et al. 2011). Volume loss and cortical thinning were also
described upon follow-up in FEP patients with heavy can-
nabis consumption (Rais et al. 2008, 2010; Habets et al.
2011). However, negative data were reported both in original
articles (Schnell et al. 2012; Wobrock et al. 2009) and a
systematic review (Malchow et al. 2012). Diffusion tensor
imaging (DTI) data on WM are not less conflicting. Chronic
cannabis use in FEP patients was associated with altered WM
microstructure, increased WM directional coherence or no
significant changes (Peters et al. 2009; Dekker et al. 2010; Ho
et al. 2011; James et al. 2011). Several methodological
limitations render difficult the interpretation of these data.
First, most of the previous studies explored either GM or
WM changes in limited series of FEP patients. Second,
positive data may reflect the concomitant presence of cog-
nitive deficits that have not been excluded in most of these
contributions. In the current investigation, we combined
neuropsychological assessment of attention and memory
performances, GM volumetry with voxel-based-morphom-
etry (VBM) (Ashburner and Friston 2000) and WM micro-
structure with tract-based-spatial-statistics (TBSS) (Smith
et al. 2006) in 50 young FEP patients with heavy, light or no
cannabis consumption. The main aim of this work is to
provide a detailed analysis of the cannabis-related structural
changes in FEP patients after controlling for the confounding
effect of cognitive status.
Materials and methods
Subjects
Fifty patients with a FEP were recruited from a specialized
inpatient service for young adults. A FEP was considered
on the presence of any DSM-IV diagnosis of a psychotic
disorder (schizophrenia, schizophreniform disorder,
schizoaffective disorder, manic or depressive episode with
psychotic symptoms and delusional disorder) with a total
duration of illness less than 1 year. For each patient, the
diagnosis at time of MRI was established by combining
information gathered from several sources (clinical pre-
sentation, relatives, staff members, and previous medical
records when available). All diagnoses were confirmed by
at least two independent psychiatrists blind to their
respective assessment (LC, FC and/or MM). In order to
cover the wide spectrum of psychosis, three diagnostic
categories were considered (Table 1): I, schizophrenia; II,
Other psychotic diagnosis (including schizoaffective dis-
order, schizophreniform disorder and delusional disorder);
III, Mood disorder with psychotic symptoms (including
manic or depressive episode with psychotic symptoms). At
the time of MRI, all patients had been receiving atypical
antipsychotic treatment (aripiprazole, clozapine, olanza-
pine, quetiapine or risperidone) for at least 2 weeks. Life-
time cannabis and substance use at time of MRI was
determined using the cannabis experience questionnaire
that was administrated by the clinical psychologist of the
care team (MA) (Di Forti et al. 2009). Subjects were not
included if they presented with a history of substance use
other than cannabis, nicotine or alcohol (use defined as
more than four separate occasions). Heavy cannabis use
was defined as near daily or more cannabis consumption
for at least 1 year prior to clinical presentation. Patients
consuming at lower frequencies prior to presentation were
categorized as light cannabis users, whereas patients with
ten lifetime cannabis consumptions or less were considered
as non-users.
Subjects were grouped as 33 users (22.7 ± 4.1 years, 4
women) and 17 non-users (23.9 ± 4.2 years, 10 women) of
cannabis. Users were further divided into 15 heavy
(23.3 ± 4.5 years, 2 women) and 18 light users
(22.2 ± 3.8 years, 2 women). The mean age at onset of
cannabis consumption was at age 15.5 ± 1.9 (age range:
13–20 years). We further divided the users according to the
age at onset in early (age 15 or less at onset) and late (age
16 or above at onset) groups. For two cases this informa-
tion was not available.
All subjects underwent neuropsychological testing of
attention and working memory performances within
2 months of MRI testing (MB or SB, fully certified neu-
ropsychologists). Attentional functions were tested using
the French computerized version of the test of attentional
performance (TAP) (Zimmerman and Fimm 1994). Visu-
ospatial and auditory working memory was evaluated with
the French version of the WMS-R span tasks (Wechsler
1981). Additional assessments included the global assess-
ment of functioning score (GAF) (Dufton and Siddique
1992) and Edinburgh handedness inventory (Oldfield
1971).
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The normal distribution of the demographic and clinical
data was tested by D’Agostino and Pearson omnibus nor-
mality tests. Normally distributed variables (age, visuo-
spatial and auditory working memory, attentional
flexibility) were analyzed using ANOVA group tests and
post-hoc pair-wise Bonferroni’s multiple comparison tests.
Variables without normal distribution (gender, handedness,
attentional inhibition) were analyzed using Kruskal–Wallis
group statistics and post-hoc pair-wise Dunn’s multiple
comparison tests.
MR Imaging
MR imaging was performed with a 1.5 T clinical routine
whole body scanner (Achieva, Philips Medical Systems,
Best, The Netherlands). 3D T1 MPRAGE: coronal acquisi-
tion, 124 slices, matrix 256 9 256, voxel size 0.94 9
0.94 9 1.5 mm3, TE 6 ms, TR 35 ms, 1 average. DTI: 30
diffusion directions, b = 1,000 s/mm2 isotropically dis-
tributed on a sphere, 1 reference b = 0 s/mm2 image with no
diffusion-weighting, axial acquisition, 70 slices, matrix
112 9 112, voxel size 2.0 9 2.0 9 2.0 mm3, TE 71.2 ms,
TR 13469.4 ms, 1 average. Additional sequences (T2w,
FLAIR) were acquired and analyzed to exclude other brain
pathology.
GM VBM Analysis of T1 Data
The VBM analysis was analyzed using the FSL software
package (http://www.fmrib.ox.ac.uk/fsl/, Version 4.1).
Standard processing steps were used, as described in detail
before (Smith et al. 2006, 2007). The essential processing
steps included brain extraction using BET (brain extraction
tool, part of FSL), tissue-type segmentation using FAST4
(part of FSL), non-linear transformation into MNI (Mon-
treal Neurological Institute) reference space and creation of
a study-specific GM template, to which the native GM
images were then non-linearly re-registered. The modu-
lated segmented images were then smoothed with an iso-
tropic Gaussian kernel with a sigma of 2 mm. Finally,
voxel-wise general linear model (GLM) was applied using
permutation-based non-parametric testing (RANDOMISE,
part of FSL), correcting for multiple comparisons imple-
menting threshold-free cluster enhancement (TFCE)
(Smith and Nichols 2009). Because of the significant dif-
ference in gender between the two groups, all calculations
were performed twice, once without and once with age and
gender as non-explanatory co-regressors. Fully corrected
p values \0.05 are considered as significant. Additionally,
the analysis was repeated with respect to the GAF score
using and age and gender as non-explanatory co-regressors.
Table 1 Demographic and clinical characteristics
Variables Cannabis users Non-users Statistical analysis
High dose Low dose
N 15 18 17
Age (years) 23.3 ± 4.5 22.2 ± 3.8 23.9 ± 4.2 NS
Gender (f/m) 2/13 2/16 10/7 Group**
high vs non*
low vs non**
GAF score 28.9 ± 10.4 33.5 ± 11.7 31.6 ± 12.1 NS
Medication type (ap/ap?ad/ap?ms) 11/2/2 15/3/0 13/3/1 NS
Medication CPZ equivalent (mg) 426.5 ± 281.5 296.2 ± 202.9 283.3 ± 262.2 NS
Diagnosis (I/II/II, see below) 9/3/3 11/1/6 6/4/7 NS
Handedness (EHI) 18.5 ± 1.7 18.6 ± 1.6 14.8 ± 7.4 NS
Visuospatial working memory (score) 17.2 ± 2.6 14.3 ± 7.9 12.0 ± 7.7 NS
Auditory working memory (score) 11.7 ± 3.4 8.9 ± 6.2 9.1 ± 6.0 NS
Attentional inhibition response time (ms) 570.0 ± 124.4 560.3 ± 91.1 556.0 ± 59.5 NS
Attentional flexibility response time (ms) 1166.0 ± 532.2 890.1 ± 202.8 1058 ± 273.1 NS
Essential demographic and clinical characteristics of the three study groups FEP subjects with high dose cannabis consumption, low dose
cannabis consumption and without concomitant cannabis consumption. Diagnoses are grouped into three categories according to DSM-IV
criteria: I, schizophrenia; II, other psychotic diagnosis (including schizoaffective disorder, schizophreniform disorder and delusional disorder);
III, mood disorder with psychotic symptoms (including manic or depressive episode with psychotic symptoms)
GAF global assessment of functioning, Ap 2nd generation antipsychotic, Ad antidepressant, Ms mood stabilizer, EHI edinburgh handedness
inventory
NS non significant (p [ 0.05); * p \ 0.05; ** p \ 0.01
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WM TBSS Analysis of DTI Data
The TBSS analysis of the DTI data was again done
implementing the FSL software package (http://www.
fmrib.ox.ac.uk/fsl/, Version 4.1), according to the stan-
dard procedure described in details (Smith et al. 2004). In
principle, TBSS projects all subjects’ FA data onto a mean
FA tract skeleton using non-linear registration. The tract
skeleton is the basis for voxel-wise cross-subject statistics
and reduces potential misregistrations as the source for
false-positive or negative results. The other DTI derived
parameters longitudinal (LD, also known as axial diffu-
sivity AD), radial (RD) and mean (MD) diffusivity were
analyzed in the same way re-using the spatial transforma-
tion parameters that were estimated in the initial FA
analysis. Similar to the VBM analysis discussed above,
voxel-wise statistical analysis was performed with TFCE
(Smith and Nichols 2009) correction for multiple com-
parisons, considering fully corrected p values \0.05 as
significant. As for the VBM analysis, all calculations were
performed twice with and without age and gender as non-
explanatory co-regressors due to the difference in gender
between groups. Equivalent to the VBM analysis, an
additional analysis was performed with respect to the GAF
score using and age and gender as non-explanatory co-
regressors.
Results
Demographic and clinical data are summarized in Table 1.
There was a clear predominance of women among non-
users (12 % of users and 59 % of non-users, p \ 0.05).
Symptomatology at initial presentation as measured by
GAF (DSM-IV) scores was consistent with clinically sig-
nificant acute psychosis (overall average score 31.5, range
15–55). There were no significant differences in age,
clinical symptom severity at initial presentation, diagnosis,
medication type and dose (chlorpromazine equivalents),
handedness, attention and memory performance between
the two groups. The average neurocognitive performance
of all groups falls within the normal age-adjusted range
(i.e. within one standard deviation of age-adjusted normal
means).
No supra-threshold differences at p \ 0.05 TFCE cor-
rected for multiple comparisons (VBM; TBSS FA, LD,
RD, MD) were found for the comparison of all users versus
non-users (see Fig. 1). In the same line, we separately
compared the groups of heavy users versus light users,
heavy users versus non-users and light users versus non-
users again yielding no supra-threshold difference (VBM;
TBSS FA, LD, RD, MD). The comparison between early
onset versus late onset, early onset versus controls and late
onset versus controls also showed no supra-threshold dif-
ferences for all MRI variables (VBM; TBSS FA, LD, RD,
MD). The inclusion of age and gender as non-explanatory
co-regressors led to similar results. The analysis with
respect to the GAF score also resulted in no supra-thresh-
old results.
Discussion
The present study did not identify changes in GM volume
and WM microstructure in FEP subjects with versus
without concomitant cannabis consumption. These nega-
tive data concerned not only light users but also young
patients with long-standing heavy consumption and do not
support the idea of cannabis-mediated neurotoxicity during
brain maturation in FEP.
The impact of cannabis consumption on brain structure
remains a highly controversial issue. Some lines of evi-
dence indicated that cannabis use in itself and in the
absence of psychosis can be deleterious for brain structure.
However, recent reviews on this subject have concluded
that overall, cannabis use has minimal or no effect on brain
structure in the general population (Martin-Santos et al.
2010; Quickfall and Crockford 2006). In respect to
Fig. 1 Illustrates the group
average grey matter (greyscale)
and white matter FA skeleton
(red–yellow) in MNI standard
space centered at MNI X = 0,
Y = 0, Z = 0. There were no
supra-threshold differences
between cannabis users and
non-users, nor between heavy
users versus light users, nor
between early onset versus late
onset
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cannabis use in psychosis, previous VBM studies in at risk
individuals, FEP and early stages of schizophrenia led to
discrepant data [for recent reviews see (Rapp et al. 2012)
(Hermann and Schneider 2012)]. The review by Rapp et al.
(2012) includes eleven studies identifying a decrease in
global or specific brain structures associated with cannabis
consumption in psychosis patients or at risk subjects. These
morphometric effects were particularly strong in brain
regions rich on cannabinoid receptors, including the cin-
gulum, the dorsolateral prefrontal cortex and the cerebel-
lum. The authors further conclude that psychosis patients
and at risk subjects might be particularly vulnerable as
similar brain volume loss is not consistently reported in
nonpsychotic and healthy samples. This vulnerability is
further supported by the recent review of Hermann and
Schneider (2012) concluding that brain alterations were
especially pronounced in schizophrenic patients with can-
nabis consumption. Furthermore, close relatives of
schizophrenic patients showed greater cannabis-associated
brain tissue loss. Nevertheless, this review also points out
that different components of cannabis might have differ-
ential effects, notably pointing to a potentially protective
effect of cannabidiol. Intriguingly, Schnell et al. found
increased GM in middle frontal gray matter in FEP patients
(Schnell et al. 2012). An increase of striatal GM density
was also reported by Potvin and coworkers in cannabis
users with psychotic symptoms (not only FEP) and con-
comitant alcohol abuse (Potvin et al. 2007). In the only
study that combined assessment of GM densities and WM
microstructure in adolescent-onset schizophrenia with
cannabis use, James et al. (2011) reported GM density loss
in the temporal fusiform gyrus, the parahippocampal gyrus,
the ventral striatum, the right middle temporal gyrus, the
insular cortex, the precuneus, the right paracingulate gyrus,
the dorsolateral prefrontal cortex, the left postcentral gyrus,
the lateral occipital cortex and the cerebellum.
DTI data in the field of cannabis use in psychosis were
not less discrepant. Supporting the idea of hyperconnec-
tivity in FEP, one recent study assessed young men with
FEP with or without cannabis consumption (Peters et al.
2009) and revealed increased directional coherence in the
bilateral uncinate fasciculus, the anterior internal capsule
and frontal WM in cannabis users. In the same line, Dekker
and collaborators reported increased vulnerability of cor-
pus callosum fibers in cannabis naı¨ve patients (Dekker
et al. 2010). In contrast to these results, decreased FA in
several brain regions including the brain stem, the internal
capsule, the corona radiata, and the superior and inferior
longitudinal fasciculus in cannabis users was reported in
adolescent-onset schizophrenia and FEP patients with early
cannabis use (Ho et al. 2011). Several methodological
differences may explain these striking discrepancies.
Firstly, most of the studies included a limited number of
cases and attempted three groups (controls, psychosis with
and without cannabis use) comparisons that limit their
statistical power. Secondly, age differences as well as
clinical parameters may further explain these discrepan-
cies. For instance, our FEP patients were older than those
of James et al. (average of 16 years) (James et al. 2011).
Diagnostic considerations may also be relevant in this
context. The majority of previous studies limited recruit-
ment to subjects diagnosed with schizophrenia. However,
in line with epidemiological evidence that cannabis con-
sumption is a risk factor for broadly defined psychosis
(James et al. 2011), our results include several forms of
psychosis. One other study (Wobrock et al. 2009) assessed
brain morphology for cannabis users and non-users
amongst subjects with more broadly defined psychosis
(schizophrenia and schizoaffective disorder) and also found
no significant structural differences. It is thus possible that
decreased GM densities and altered WM microstructure
may characterize a subgroup of very young FEP patients
with increased vulnerability to cannabis consumption. One
additional parameter to take into account here is the dose
and duration of cannabis consumption that is highly vari-
able among the previously cited studies. In the present
series, both dose and duration of cannabis consumption
were not related to MRI parameters. Moreover, all of our
cases were cognitively preserved at least for attention and
working memory. It is thus likely that our FEP cannabis
users had a less aggressive form of their disease not
associated with cognitive deficits in early life.
Strengths and Limitations
Since the main issue to address concerns the deleterious
effects of cannabis in FEP, this investigation includes only
clinically overt cases without comparisons with an ad hoc
control group. The present study has two main strengths.
Firstly, it combines GM densities and WM microstructure
investigation using a strict correction for multiple com-
parisons. Secondly, cannabis users and non-users did not
differ in terms of cognitive performances precluding the
presence of MRI differences that could be attributed to this
confounding factor. However, several limitations should
also be considered. The major limitation of the current
investigation is the relatively small sample size of 50 FEP
subjects. One should, however, consider that this sample
size of prospectively assessed FEP subjects with high MRI
data quality without for example motion artifacts is com-
parable to that of previous studies in this field. Despite the
comparable medication load at inclusion, we cannot for-
mally exclude that the chronic administration of these
agents may alter the quality of our observations. In fact,
previous studies showed that both typical and atypical
antipsychotics often display contradictory impacts on both
Brain Topogr (2013) 26:641–647 645
123
GM and WM volumes (Ho et al. 2011; Smieskova et al.
2009; Navari and Dazzan 2009). However, this is an
unlikely scenario given the young age of the present
cohort.
The inverse conclusion, notably the absence of canna-
bis-related alterations in FEP subjects, is not warranted by
the current investigation for two main reasons. Firstly, the
TFCE multiple comparison correction compensates for
false positive but not false negative results since the sample
size of 50 consecutive subjects might have insufficient
statistical power to detect subtle yet significant group dif-
ferences in MRI parameters. However, even if present, it is
highly unlikely that such subtle cannabis-related alterations
in GM and WM would have a major effect on the long-
term evolution of FEP. Future longitudinal studies on
young and adult FEP patients combining structural and
functional MRI imaging, neuropsychological evaluation
including activation paradigms and quantitative assessment
of cannabis use are needed to explore the effect of the long-
term consumption of this drug on brain structure and
reactivity across the age spectrum of this disorder.
Conflict of interest The authors declare that they have no conflict
of interest.
References
Amminger GP, Harris MG, Conus P, Lambert M, Elkins KS, Yuen
HP, McGorry PD (2006) Treated incidence of first-episode
psychosis in the catchment area of EPPIC between 1997 and
2000. Acta Psychiatr Scand 114:337–345
Ashburner J, Friston KJ (2000) Voxel-based morphometry: the
methods. Neuroimage 11:805–821
Bangalore SS, Prasad KM, Montrose DM, Goradia DD, Diwadkar
VA, Keshavan MS (2008) Cannabis use and brain structural
alterations in first episode schizophrenia: a region of interest,
voxel based morphometric study. Schizophr Res 99:1–6
Cohen M, Rasser PE, Peck G, Carr VJ, Ward PB, Thompson PM,
Johnston P, Baker A, Schall U (2011) Cerebellar grey-matter
deficits, cannabis use and first-episode schizophrenia in adoles-
cents and young adults. Int J Neuropsychopharmacol 4:1–11
Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH,
de Haan L (2010) Cannabis use and callosal white matter
structure and integrity in recent-onset schizophrenia. Psychiatry
Res 181:51–56
Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques
TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA,
Wiffen B, Powell J, Murray RM (2009) High-potency cannabis
and the risk of psychosis. Br J Psychiatry 195:488–491
Dufton BD, Siddique CM (1992) Measures in the day hospital. I. The
global assessment of functioning scale. Int J Partial Hosp
8:41–49
Fornito A, Yucel M, Patti J, Wood SJ, Pantelis C (2009) Mapping
grey matter reductions in schizophrenia: an anatomical likeli-
hood estimation analysis of voxel-based morphometry studies.
Schizophr Res 108:104–113
Fusar-Poli P, Borgwardt S, Crescini A, Deste G, Kempton MJ, Lawrie
S, Mc Guire P, Sacchetti E (2011) Neuroanatomy of
vulnerability to psychosis: a voxel-based meta-analysis. Neuro-
sci Biobehav Rev 35:1175–1185
Glahn DC, Laird AR, Ellison-Wright I, Thelen SM, Robinson JL,
Lancaster JL, Bullmore E, Fox PT (2008) Meta-analysis of gray
matter anomalies in schizophrenia: application of anatomic
likelihood estimation and network analysis. Biol Psychiatry
64:774–781
Habets P, Marcelis M, Gronenschild E, Drukker M, van Os J (2011)
Reduced cortical thickness as an outcome of differential
sensitivity to environmental risks in schizophrenia. Biol Psychi-
atry 69:487–494
Henquet C, Murray R, Linszen D, van Os J (2005) The environment
and schizophrenia: the role of cannabis use. Schizophr Bull
31:608–612
Hermann D, Schneider M (2012) Potential protective effects of
cannabidiol on neuroanatomical alterations in cannabis users and
psychosis: a critical review. Curr Pharm Des 18:4897–4905
Ho BC, Wassink TH, Ziebell S, Andreasen NC (2011) Cannabinoid
receptor 1 gene polymorphisms and marijuana misuse interac-
tions on white matter and cognitive deficits in schizophrenia.
Schizophr Res 128:66–75
Honea R, Crow TJ, Passingham D, Mackay CE (2005) Regional
deficits in brain volume in schizophrenia: a meta-analysis of
voxel-based morphometry studies. Am J Psychiatry 162:
2233–2245
James A, Hough M, James S, Winmill L, Burge L, Nijhawan S,
Matthews PM, Zarei M (2011) Greater white and grey matter
changes associated with early cannabis use in adolescent-onset
schizophrenia (AOS). Schizophr Res 128:91–97
Kyriakopoulos M, Frangou S (2009) Recent diffusion tensor imaging
findings in early stages of schizophrenia. Curr Opin Psychiatry
22:168–176
Malchow B, Hasan A, Fusar-Poli P, Schmitt A, Falkai P, Wobrock T
(2012) Cannabis abuse and brain morphology in schizophrenia: a
review of the available evidence. Eur Arch Psychiatry Clin
Neurosci 263(1):3–13
Martin-Santos R, Fagundo AB, Crippa JA, Atakan Z, Bhattacharyya
S, Allen P, Fusar-Poli P, Borgwardt S, Seal M, Busatto GF,
McGuire P (2010) Neuroimaging in cannabis use: a systematic
review of the literature. Psychol Med 40:383–398
Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB,
Burke M, Lewis G (2007) Cannabis use and risk of psychotic or
affective mental health outcomes: a systematic review. Lancet
370:319–328
Navari S, Dazzan P (2009) Do antipsychotic drugs affect brain
structure? a systematic and critical review of MRI findings.
Psychol Med 39:1763–1777
Oldfield RC (1971) The assessment and analysis of handedness: the
Edinburgh inventory. Neuropsychologia 9:97–113
Peters BD, de Haan L, Vlieger EJ, Majoie CB, den Heeten GJ,
Linszen DH (2009) Recent-onset schizophrenia and adolescent
cannabis use: MRI evidence for structural hyperconnectivity?
Psychopharmacol Bull 42:75–88
Potvin S, Mancini-Marie A, Fahim C, Mensour B, Levesque J,
Karama S, Beauregard M, Rompre PP, Stip E (2007) Increased
striatal gray matter densities in patients with schizophrenia and
substance use disorder: a voxel-based morphometry study.
Psychiatry Res 154:275–279
Quickfall J, Crockford D (2006) Brain neuroimaging in cannabis use:
a review. J Neuropsychiatry Clin Neurosci 18:318–332
Rais M, Cahn W, Van Haren N, Schnack H, Caspers E, Hulshoff Pol
H, Kahn R (2008) Excessive brain volume loss over time in
cannabis-using first-episode schizophrenia patients. Am J Psy-
chiatry 165:490–496
Rais M, van Haren NE, Cahn W, Schnack HG, Lepage C, Collins L,
Evans AC, Hulshoff Pol HE, Kahn RS (2010) Cannabis use and
646 Brain Topogr (2013) 26:641–647
123
progressive cortical thickness loss in areas rich in CB1 receptors
during the first five years of schizophrenia. Eur Neuropsycho-
pharmacol 20:855–865
Rapp C, Bugra H, Riecher-Rossler A, Borgwardt S (2012) Effects of
cannabis use on human brain structure in psychosis: a systematic
review combining in vivo structural neuroimaging and post-
mortem studies. Curr Pharm Des 18(32):5070–5080
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL,
Goodwin FK (1990) Comorbidity of mental disorders with
alcohol and other drug abuse. Results from the epidemiologic
catchment area (ECA) study. JAMA 264:2511–2518
Schnell T, Kleiman A, Gouzoulis-Mayfrank E, Daumann J, Becker B
(2012) Increased gray matter density in patients with schizo-
phrenia and cannabis use: a voxel-based morphometric study
using DARTEL. Schizophr Res 138(2–3):183–187
Semple DM, McIntosh AM, Lawrie SM (2005) Cannabis as a risk
factor for psychosis: systematic review. J Psychopharmacol
19:187–194
Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD,
Drewe J, Radue EW, McGuire PK, Riecher-Rossler A, Borg-
wardt SJ (2009) The effects of antipsychotics on the brain: what
have we learnt from structural imaging of schizophrenia? a
systematic review. Curr Pharm Des 15:2535–2549
Smith SM, Nichols TE (2009) Threshold-free cluster enhancement:
addressing problems of smoothing, threshold dependence and
localisation in cluster inference. Neuroimage 44:83–98
Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE,
Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney
DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N,
Brady JM, Matthews PM (2004) Advances in functional and
structural MR image analysis and implementation as FSL.
Neuroimage 23(Suppl 1):S208–S219
Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE,
Mackay CE, Watkins KE, Ciccarelli O, Cader MZ, Matthews
PM, Behrens TE (2006) Tract-based spatial statistics: voxelwise
analysis of multi-subject diffusion data. Neuroimage 31:
1487–1505
Smith SM, Johansen-Berg H, Jenkinson M, Rueckert D, Nichols TE,
Miller KL, Robson MD, Jones DK, Klein JC, Bartsch AJ,
Behrens TE (2007) Acquisition and voxelwise analysis of multi-
subject diffusion data with tract-based spatial statistics. Nat
Protoc 2:499–503
Szeszko PR, Robinson DG, Sevy S, Kumra S, Rupp CI, Betensky JD,
Lencz T, Ashtari M, Kane JM, Malhotra AK, Gunduz-Bruce H,
Napolitano B, Bilder RM (2007) Anterior cingulate grey-matter
deficits and cannabis use in first-episode schizophrenia. Br J
Psychiatry 190:230–236
Wechsler D (1981) Adult Intelligence Scale, revised (WAIS-R).
Psychological Corporation, San Antonio, TX
Wobrock T, Sittinger H, Behrendt B, D’Amelio R, Falkai P (2009)
Comorbid substance abuse and brain morphology in recent-onset
psychosis. Eur Arch Psychiatry Clin Neurosci 259:28–36
Zimmerman P, Fimm B (1994) Tests d’evaluation de l’attention
(TEA) (Version 1.02, franc¸aise). Psytest, Wu¨rselen
Brain Topogr (2013) 26:641–647 647
123
